Related references
Note: Only part of the references are listed.Distribution of segmental chromosomal alterations in neuroblastoma
A. Juan Ribelles et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Jennifer H. Foster et al.
CLINICAL CANCER RESEARCH (2021)
ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside
Johannes H. Schulte et al.
CLINICAL CANCER RESEARCH (2021)
Extensive Clonal Branching Shapes the Evolutionary History of High-Risk Pediatric Cancers
Natalie Andersson et al.
CANCER RESEARCH (2020)
Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma
Richard P. Koche et al.
NATURE GENETICS (2020)
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
Robert Vander Velde et al.
NATURE COMMUNICATIONS (2020)
Pervasive chromosomal instability and karyotype order in tumour evolution
Thomas B. K. Watkins et al.
NATURE (2020)
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations
Samuel W. Brady et al.
NATURE COMMUNICATIONS (2020)
Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma
Konstantin Helmsauer et al.
NATURE COMMUNICATIONS (2020)
Terry Fox PRecision Oncology For Young peopLE (PROFYLE): A Canadian precision medicine program for children, adolescents and young adults with hard-to-treat cancer
Stephanie A. Grover et al.
CANCER RESEARCH (2020)
Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction
Constantin Peitz et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
Ricky M. Trigg et al.
NATURE COMMUNICATIONS (2019)
The UCSC Genome Browser database: 2019 update
Maximilian Haeussler et al.
NUCLEIC ACIDS RESEARCH (2019)
GENCODE reference annotation for the human and mouse genomes
Adam Frankish et al.
NUCLEIC ACIDS RESEARCH (2019)
The challenge of defining ultra-high-risk neuroblastoma
Daniel A. Morgenstern et al.
PEDIATRIC BLOOD & CANCER (2019)
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
Diana Cervantes-Madrid et al.
SCIENTIFIC REPORTS (2019)
Extrachromosomal oncogene amplification in tumour pathogenesis and evolution
Roel G. W. Verhaak et al.
NATURE REVIEWS CANCER (2019)
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
David T. W. Jones et al.
NATURE REVIEWS CANCER (2019)
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
Samra Turajlic et al.
CELL (2018)
The landscape of genomic alterations across childhood cancers
Susanne N. Groebner et al.
NATURE (2018)
Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer
Jenny Karlsson et al.
NATURE GENETICS (2018)
Intratumor heterogeneity defines treatment-resistant HER2+breast tumors
Inga H. Rye et al.
MOLECULAR ONCOLOGY (2018)
A mechanistic classification of clinical phenotypes in neuroblastoma
Sandra Ackermann et al.
SCIENCE (2018)
COSMIC: somatic cancer genetics at high-resolution
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2017)
Neuroblastoma is composed of two super-enhancer-associated differentiation states
Tim van Groningen et al.
NATURE GENETICS (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma
Marco Lodrini et al.
ONCOTARGET (2017)
Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015
Frank Berthold et al.
PEDIATRIC DRUGS (2017)
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
Hui Qin Wang et al.
ELIFE (2017)
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
Noemi Andor et al.
NATURE MEDICINE (2016)
Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study
Barbara C. Worst et al.
EUROPEAN JOURNAL OF CANCER (2016)
The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma
Dominik Bogen et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling
Aubin Moutal et al.
CANCER RESEARCH (2015)
Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis
Angela Bellini et al.
CLINICAL CANCER RESEARCH (2015)
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Navin R. Pinto et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Telomerase activation by genomic rearrangements in high-risk neuroblastoma
Martin Peifer et al.
NATURE (2015)
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld et al.
NATURE GENETICS (2015)
Mutational dynamics between primary and relapse neuroblastomas
Alexander Schramm et al.
NATURE GENETICS (2015)
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
Roland F. Schwarz et al.
PLOS MEDICINE (2015)
Comparison of RNA-seq and microarray-based models for clinical endpoint prediction
Wenqian Zhang et al.
GENOME BIOLOGY (2015)
Detection of tumor ALK status in neuroblastoma patients using peripheral blood
Valerie Combaret et al.
CANCER MEDICINE (2015)
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data
F. Favero et al.
ANNALS OF ONCOLOGY (2015)
Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma
Fei Xu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution
Christopher A. Miller et al.
PLOS COMPUTATIONAL BIOLOGY (2014)
Phylogenetic Quantification of Intra-tumour Heterogeneity
Roland F. Schwarz et al.
PLOS COMPUTATIONAL BIOLOGY (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Targeted Therapy for Neuroblastoma: ALK Inhibitors
J. H. Schulte et al.
KLINISCHE PADIATRIE (2013)
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh et al.
NATURE GENETICS (2013)
An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data
Yuichi Shiraishi et al.
NUCLEIC ACIDS RESEARCH (2013)
Cancer chromosomal instability: therapeutic and diagnostic challenges
Nicholas McGranahan et al.
EMBO REPORTS (2012)
A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3
Pablo Cingolani et al.
FLY (2012)
Chromosomal Instability Confers Intrinsic Multidrug Resistance
Alvin J. X. Lee et al.
CANCER RESEARCH (2011)
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
P. F. Ambros et al.
BRITISH JOURNAL OF CANCER (2009)
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
Isabelle Janoueix-Lerosey et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification
Sven Bilke et al.
CLINICAL CANCER RESEARCH (2008)
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George et al.
NATURE (2008)
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Isabelle Janoueix-Lerosey et al.
NATURE (2008)
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
Frank Westermann et al.
GENOME BIOLOGY (2008)
Chromosome 1p and 11q deletions and outcome in neuroblastoma
EF Attiyeh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?
RL Stallings et al.
CANCER GENETICS AND CYTOGENETICS (2003)
Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy
P Duesberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
